
The Eye as a Biomarker: Why Retinal AI Could Reshape How Trials Screen and Stratify Pregnant Patients
<a href="https://news.google.com/rss/articles/CBMi-AFBVV95cUxQakZXN1dvVWxIeVNyd1AzbExXQ3plbGc4ZG9VMFNCSlNOQnJxdURNVG95UWhmaDFobDh1Vnd6ZnRBUkhKRFlIWWVFMFZXbGNfNXVyVEl5NDlyVGt2WjRoX2MybEZ5TTFLWUFPblRFYTd5OHZkVl9pZ1BBR1lWUmdEZWxmTDdmYllfTnNxWjVINkp1QlA1N3JVYWt4Z3k2NXBNYVlleVdzRmV5MGI5cEpzaXFfMko2cTE5UHNuUkZRZDJTZ1BrTmRKYjFxYzE1QWw5V3dlZ2owTmdORXFyd3d5bTRUMHpNV3lOeXVBV25aS3plS0p2c1dVRg?oc=5" target="_blank">The Eye as a Biomarker: Why Retinal AI Could Reshape How Trials Screen and Stratify Pregnant Patients</a>&nbsp;&nbsp;<font color="#6f6f6f">The Clinical Trial Vanguard</font>
